Skip to content

Role of MRI in Breast Cancer Subtypes

Role of MRI in Detection of Breast Cancer Molecular Subtypes in Correlation With Immunohistochemistry Results

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06707584
Acronym
MRI
Enrollment
45
Registered
2024-11-27
Start date
2025-04-01
Completion date
2030-12-01
Last updated
2024-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MRI in Breast Cancer

Brief summary

efficacy of MRI in detection of breast cancer molecular subtypes instead of biopsy and immunohistochemistry

Detailed description

2.4.4 -Study tools (in detail, e.g., lab methods, instruments, steps, chemicals, …): Patient with breast cancer (malignant breast mass) will do MRI breast and molecular subtypes will be assessed MRI imaging studies will performed on a 1.5 T scanner , The patient is placed in the prone position with both breasts placed adequately in a double breast coil (four-channel phased array coil), MRI sequences are: 1\. Axial T1WI. 2. Axial T2WI. 3. Axial STIR. 4. DCE-MRI with post-processing subtraction images 5- Axial DWI at b value( 0, 400, 800 and 1000 mm\^2 per second) and ADC map will performed 6. MRI spectroscopy MRI acquisition protocol MRI protocols includes * Axial T2-weighted fast spin echo sequence: TR=3840 ms, TE=81 ms, slice thickness=3.5 mm, and matrix=448×448. * Coronal T2-weighted fast spin echo sequence: TR=3840 ms, TE=81 ms, slice thickness=3.5 mm, and matrix=448×448.s * Short tau inversion recovery - axial: TR=8540 ms, TE=59 ms, TI=170 ms, slice thickness=3.5 mm, and matrix=320×314.4. * The standard dynamic protocol commenced with a coronal three-dimensional rapid Field echo (thrive) sense non-enhanced T1-weighted sequence. * A gadolinium containing contrast was administered at a dose of 0.2 ml/ kg by power injection at a speed of 2.0 ml/s and flushed with 20 ml of saline solution at the same rate. * Dynamic imaging was then done in five consecutive series at 90-s intervals. Standard subtraction images were obtained by subtracting precontract images from the early peak postcontrast image.

Interventions

None listed

Sponsors

Lamiaa Gomaa Ahmed Elsayed
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

a. patients with breast cancer confirmed by histopathology,

Exclusion criteria

1. breast implants 2. general Contraindication of MRI as claustrophobia

Design outcomes

Primary

MeasureTime frameDescription
accuracy of MRI in breast cancer subtyping5 yearsTo investigate the diagnostic accuracy of dynamic post contrast imaging MRI in evaluation of breast cancer molecular subtypes and DWI and ADC in detection of breast cancer molecular subtypes

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026